KRAS and neoplasm: In this way, targeting ER stress resistance in combination with ER stress-inducing drugs, like IPI-504 40 or bortezomib,41, 42 represents a promising preventive or therapeutic strategy against aggressive KRAS-driven tumours like pancreatic cancer.